British drugmaker AstraZeneca (LSE: AZN) and co-developer Merck & Co (NYSE: MRK) have been granted a new European approval for the PARP blocker Lynparza (olaparib).
The European Medicines Agency (EMA) has approved the therapy for some people with metastatic castration-resistant prostate cancer (mCRPC), as defined by certain genetic mutations.
Lynparza is the first and only therapy of this kind approved in Europe in biomarker-selected advanced prostate cancer. The decision was widely anticipated, following a positive recommendation from the EMA’s scientific panel in September.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze